Home

Mark Basik

Academic title(s): 

Herbert Black Professor of Surgical Oncology

Contact Information
Email address: 
mark.basik [at] mcgill.ca
Location: 
Jewish General Hospital
Division: 
General Surgery
Hospital title: 
Surgical Oncologist
Degree(s): 

MDCM

Current research: 

Drug resistance and liquid biopsy in breast cancer
http://www.ladydavis.ca/en/basiklab

Clinical Interests: 

Breast cancer

Language(s) spoken: 
English
French
Italian
Polish
Biography: 

Dr. Mark Basik was born in Montreal, graduated in medicine from McGill University, completed a general Surgery Residency at the Université de Montreal, followed by a fellowship in Surgical Oncology at Roswell Park Cancer Institute. He was a visiting investigator at the National Institutes of Health in Bethesda. He returned to Montreal in 2003, where he is now practicing breast cancer surgery at the Jewish General Hospital in Montreal, QC, and he is the Herbert Black professor of Surgical Oncology at McGill University. He heads the Cancer Genomics and Translational Research Laboratory at the Lady Davis Institute for Medical Research. His research interests include understanding the causes of resistance to therapy in breast cancer as well as developing new diagnostic blood tests for breast cancer.

Selected publications: 

https://pubmed.ncbi.nlm.nih.gov/?term=Basik+M&sort=date

Recent articles:

Early, On-Treatment Levels and Dynamic Changes of Genomic Instability in Circulating Tumor DNA Predict Response to Treatment and Outcome in Metastatic Breast Cancer Patients.

Aguilar-Mahecha A, Lafleur J, Brousse S, Savichtcheva O, Holden KA, Faulkner N, McLennan G, Jensen TJ, Basik M. Cancers (Basel). 2021 Mar 16;13(6):1331. doi: 10.3390/cancers13061331.

Prognostic and predictive value of circulating tumor DNA during neoadjuvant chemotherapy for triple negative breast cancer.

Cavallone L, Aguilar-Mahecha A, Lafleur J, Brousse S, Aldamry M, Roseshter T, Lan C, Alirezaie N, Bareke E, Majewski J, Ferrario C, Hassan S, Discepola F, Seguin C, Mihalcioiu C, Marcus EA, Robidoux A, Roy JA, Pelmus M, Basik M. Sci Rep. 2020 Sep 7;10(1):14704. doi: 10.1038/s41598-020-71236-y.

A Unique Morphological Phenotype in Chemoresistant Triple-Negative Breast Cancer Reveals Metabolic Reprogramming and PLIN4 Expression as a Molecular Vulnerability.

Sirois I, Aguilar-Mahecha A, Lafleur J, Fowler E, Vu V, Scriver M, Buchanan M, Chabot C, Ramanathan A, Balachandran B, Légaré S, Przybytkowski E, Lan C, Krzemien U, Cavallone L, Aleynikova O, Ferrario C, Guilbert MC, Benlimame N, Saad A, Alaoui-Jamali M, Saragovi HU, Josephy S, O'Flanagan C, Hursting SD, Richard VR, Zahedi RP, Borchers CH, Bareke E, Nabavi S, Tonellato P, Roy JA, Robidoux A, Marcus EA, Mihalcioiu C, Majewski J, Basik M. Mol Cancer Res. 2019 Dec;17(12):2492-2507. doi: 10.1158/1541-7786.MCR-19-0264. Epub 2019 Sep 19.

Metastatic Breast Carcinoma-Associated Fibroblasts Have Enhanced Protumorigenic Properties Related to Increased IGF2 Expression.

Gui Y, Aguilar-Mahecha A, Krzemien U, Hosein A, Buchanan M, Lafleur J, Pollak M, Ferrario C, Basik M. Clin Cancer Res. 2019 Dec 1;25(23):7229-7242. doi: 10.1158/1078-0432.CCR-19-1268. Epub 2019 Sep 12.

Follow us on:

Back to top